Vyleesi Pharmacokinetics (ADME): How Bremelanotide Is Absorbed, Distributed, Metabolized, and Eliminated

Mechanism of Action: MC4R Agonism in the Central Nervous System

Bremelanotide activates melanocortin-4 receptors in hypothalamic and limbic circuits tied to sexual arousal, appetite, and autonomic tone. This is a nonspecific pathway. The drug also shows affinity for MC1R and MC3R, which partly explains its effect on blood pressure and its historical link to synthetic melanotropin research.

The compound is a cyclic analog of alpha-melanocyte-stimulating hormone (alpha-MSH). Its seven-amino-acid ring structure resists enzymatic breakdown better than linear MSH peptides, which accounts for its subcutaneous viability 1. Unlike oral small-molecule drugs for sexual dysfunction (such as flibanserin, a 5-HT1A agonist), bremelanotide works downstream of serotonergic and dopaminergic modulation. It directly engages melanocortin signaling in the medial preoptic area and ventromedial hypothalamus 2.

The RECONNECT trials (N=1,247 across two Phase 3 studies) demonstrated that bremelanotide 1.75 mg SC produced statistically significant improvements in desire and distress scores versus placebo over 24 weeks in premenopausal women with hypoactive sexual desire disorder (HSDD) 3. The pharmacologic onset of desire-related central effects aligned with the plasma Tmax window of 1 to 1.5 hours.

Absorption: Rapid and Nearly Complete From Subcutaneous Tissue

Subcutaneous bioavailability of bremelanotide is approximately 100%. The drug does not require first-pass hepatic processing because peptide absorption from the subcutaneous depot enters systemic circulation directly via capillary uptake.

Peak plasma concentration (Cmax) after a 1.75 mg dose reaches roughly 80.3 ng/mL, with a median Tmax of 1 hour 1. Absorption is consistent across abdominal injection sites. The coefficient of variation for Cmax is approximately 40%, a figure typical for SC peptide therapeutics 4. Food does not affect bioavailability because the drug bypasses the gastrointestinal tract entirely.

A point worth noting for clinicians: the 45-minute pre-activity dosing recommendation in the label is based on the Tmax data. Sexual desire effects in trial participants correlated with plasma concentrations above 50 ng/mL, a threshold typically reached within 30 to 45 minutes of injection 1. Dose-proportional pharmacokinetics were observed across the 0.3 mg to 4.0 mg range studied in Phase 1 trials, confirming linear absorption kinetics 5.

Distribution: Low Protein Binding, Moderate Volume

Bremelanotide distributes into a volume of approximately 20.4 L. That number suggests distribution beyond plasma into extracellular fluid and some tissue uptake, but not extensive lipophilic partitioning. For a 70 kg patient, a Vd of 20.4 L corresponds to roughly 0.29 L/kg 1.

Plasma protein binding is low at 21%. This is clinically relevant for two reasons. First, displacement interactions with highly protein-bound co-medications are unlikely. Second, the free fraction available for receptor engagement is high relative to total plasma drug concentration 6.

Bremelanotide does cross the blood-brain barrier. MC4R-mediated CNS effects (desire modulation, transient blood pressure elevation, nausea) confirm central penetration. Preclinical autoradiography in rats showed measurable radioactivity in hypothalamic tissue within 30 minutes of SC dosing 2. The peptide's cyclic structure and relatively small molecular weight (1,025 Da) support limited but functionally sufficient CNS access.

Metabolism: Hydrolytic Peptide Cleavage, Not CYP-Dependent

Bremelanotide does not rely on cytochrome P450 enzymes for its primary metabolic clearance. This is one of the most clinically useful features of its pharmacokinetic profile. The drug is degraded by nonspecific peptidases into smaller, inactive peptide fragments 1.

In vitro studies using human liver microsomes showed that bremelanotide is not a substrate, inhibitor, or inducer of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 at clinically relevant concentrations 7. This means the drug carries a low risk of pharmacokinetic drug-drug interactions mediated through hepatic oxidative metabolism.

The cyclic heptapeptide ring is cleaved by endopeptidases in plasma and peripheral tissues. The resulting fragments (di- and tripeptides, individual amino acids) enter normal amino acid catabolism. No single active metabolite has been identified. The FDA's clinical pharmacology review confirmed that metabolite profiling in plasma and urine did not reveal any circulating species with MC4R activity 7.

One interaction does matter, though. Bremelanotide slows gastric emptying. Co-administration with oral naltrexone 50 mg delayed naltrexone Tmax by 1 hour and reduced its Cmax by 28%, though overall AUC was unchanged 1. The FDA label advises separating bremelanotide from oral medications that depend on rapid onset, as delayed gastric transit can blunt their peak effect.

Excretion: Renal Predominance With a Short Half-Life

The terminal elimination half-life of bremelanotide is approximately 2.7 hours. This short half-life supports the drug's as-needed dosing model and explains why accumulation does not occur at the recommended maximum frequency of once daily 1.

Renal excretion accounts for approximately 64.8% of the administered dose, recovered in urine as parent drug and peptide fragments. Fecal recovery accounts for roughly 22.8% 7. Total clearance is about 47.8 L/hr, a rate consistent with a combination of renal filtration and extravascular peptide hydrolysis.

In patients with mild renal impairment (eGFR 60 to 89 mL/min), AUC increased by approximately 17%, a change the FDA did not consider clinically meaningful. Moderate renal impairment (eGFR 30 to 59 mL/min) raised AUC by about 40%. The drug has not been studied in severe renal impairment or end-stage renal disease 1. Dr. Sheryl Kingsberg, a lead investigator on the RECONNECT program, noted in a 2019 review: "The short half-life and predictable renal clearance make bremelanotide pharmacokinetically straightforward for most patients, though caution in moderate-to-severe renal dysfunction is prudent" 3.

Special Populations: Hepatic Impairment, Body Weight, and Race

Hepatic impairment meaningfully alters bremelanotide exposure. In a dedicated pharmacokinetic study, subjects with moderate hepatic impairment (Child-Pugh B) showed a 30% increase in AUC and a 44% increase in Cmax compared to matched controls 7. Mild impairment (Child-Pugh A) produced no significant PK changes. The drug has not been studied in severe hepatic impairment (Child-Pugh C), and the label does not recommend use in that population.

Body weight influences exposure modestly. Population PK modeling showed that a 100 kg woman has roughly 20% lower Cmax than a 60 kg woman receiving the same 1.75 mg dose, attributable to the larger volume of distribution 7. The FDA did not require weight-based dosing because efficacy endpoints in the RECONNECT trials did not differ significantly by BMI subgroup 3.

Race-based PK analyses showed no clinically significant differences between Black, White, and Hispanic participants in the pooled Phase 3 dataset 7. Age effects were also minimal within the studied premenopausal range (18 to 54 years).

Drug Interactions: The Gastric Motility Effect and Pharmacodynamic Overlap

The most important drug interaction with bremelanotide is pharmacodynamic, not pharmacokinetic. Because bremelanotide transiently raises blood pressure (mean increase of 6/3 mmHg at Tmax), co-administration with antihypertensives or drugs that lower blood pressure may produce unpredictable hemodynamic swings 1. The FDA specifically contraindicates concurrent use with naltrexone-containing products, not because of a PK interaction, but because the 28% Cmax reduction of naltrexone could compromise its therapeutic effect in patients using it for alcohol or opioid dependence.

The gastric emptying delay is the primary PK-level interaction. Phase 1 crossover studies showed the delay was consistent and reproducible. Indomethacin Cmax decreased by approximately 25% when co-dosed with bremelanotide, though AUC was unaffected 7. Clinicians prescribing bremelanotide alongside time-sensitive oral medications (antimigraine triptans, short-acting analgesics, anxiolytics used for acute episodes) should advise patients to stagger dosing by at least 1 to 2 hours.

Bremelanotide is not a substrate or inhibitor of P-glycoprotein, OATP1B1, OATP1B3, OAT1, OAT3, OCT2, MATE1, or MATE2-K transporters 7. This transporter profile further confirms the low interaction risk at the metabolic level.

Clinical PK Summary: What the Numbers Mean for Prescribers

The 2.7-hour half-life means bremelanotide is essentially cleared within 12 hours of dosing. Fewer than 3% of patients in the RECONNECT studies reported next-day residual effects 3. The 8-dose monthly cap in the FDA label is not based on accumulation risk but on the nausea and blood pressure signal observed at higher dosing frequencies during Phase 2 dose-finding studies 5.

For patients with moderate hepatic impairment, the 30% AUC increase translates to an estimated Cmax near 115 ng/mL versus the typical 80 ng/mL. Because nausea incidence rose sharply at exposures above 120 ng/mL in Phase 1 dose-escalation data, these patients may experience more pronounced side effects at the standard 1.75 mg dose 7. The Endocrine Society's 2019 commentary on melanocortin-targeted therapeutics stated: "Peptide-based sexual health drugs offer favorable metabolic profiles compared to small molecules, but clinicians must remain attentive to exposure shifts in organ impairment populations" 8.

The recommended clinical instruction: inject 1.75 mg SC into the abdomen at least 45 minutes before anticipated sexual activity, no more than once in 24 hours, with awareness that co-administered oral medications may have delayed absorption for 2 to 3 hours post-dose.